• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: A.I.D.D LONGFORD ARCHITECT TOTAL B-HCG

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

A.I.D.D LONGFORD ARCHITECT TOTAL B-HCG Back to Search Results
Catalog Number 07K78-30
Device Problem False Negative Result (1225)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 09/05/2017
Event Type  malfunction  
Manufacturer Narrative
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.(b)(6).
 
Event Description
The customer reports that one female patient had generated negative architect total b-hcg assay results on two different dates, (b)(6) 2017 (sid (b)(6); <1.2 miu/ml) and (b)(6) 2017 (sid (b)(6); <1.2 miu/ml).The patient had commented on both occasions that she had not had her period.The patient went to a different lab where a new sample was collected and a positive b-hcg result was generated.Also, the patient tested b-hcg positive with an over the counter pregnancy test.On two different dates, this patient had generated initial (b)(6) architect qual ii assay results of (b)(6) on (b)(6) 2017) and (b)(6), (sid (b)(6) on (b)(6) 2017).It was the low (b)(6) assay results that lead the patient to consult a specialist who discovered the pregnancy by an ultrasound (performed on (b)(6) 2017) and verified that the patient was (b)(6) months pregnant.The patient has been diagnosed with a bipartite uterus and an at risk pregnancy.(b)(6) results were (b)(6).There is no impact to patient management reported.
 
Manufacturer Narrative
A review of complaint tracking and trending metrics was performed and identified no adverse trends or systemic issues in conjunction with the complaint incident currently under evaluation.The historical performance of reagent lot 70091ui00 was evaluated using world wide data.The patient data was analyzed and compared to an established control limit.This evaluation indicated that the patient median result for lot 70091ui00 is within the established control limits.Therefore, no unusual reagent lot performance was identified for lot 70091ui00.In addition, a device history record review was performed on lot 70091ui00, which did not show any potential non-conformances, deviations, or non-conformances.The architect total b-hcg assay package insert and the architect system operations manual provide information to address the current customer issue.Based on the available information from the customer site and the results of this evaluation, there is no evidence to reasonably suggest that a systemic issue or product deficiency exists.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT TOTAL B-HCG
Type of Device
B-HCG
Manufacturer (Section D)
A.I.D.D LONGFORD
lisnamuck
co. longford
longford NA
EI  NA
MDR Report Key7157811
MDR Text Key96708249
Report Number3005094123-2018-00002
Device Sequence Number1
Product Code DHA
UDI-Device Identifier00380740014971
UDI-Public00380740014971
Combination Product (y/n)N
PMA/PMN Number
K983424
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 02/21/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/02/2018
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date11/14/2017
Device Catalogue Number07K78-30
Device Lot Number70091UI00
Was Device Available for Evaluation? No
Date Manufacturer Received02/21/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARCHITECT I2000SR ANALYZER; ARCHITECT I2000SR ANALYZER; LN: 03M74-02 SN: (B)(4); LN: 03M74-02 SN: (B)(4)
-
-